For a set of common physician services, employer-sponsored Medicare Advantage plans are found to pay prices that are similar to traditional Medicare rates.
Successful patient engagement in a nationally available, remotely delivered behavioral health intervention can significantly improve medical outcomes and lower healthcare costs.
This article recommends quality measures for exchange health plans and strategies to increase the availability of quality results for public reporting.
Compared with Japan, the United States has substantially less geographic variation in surgical outcomes, but it has higher variation in cost.
Optimal end-stage renal disease (ESRD) starts were associated with lower 12-month morbidity, mortality, and inpatient and outpatient utilization in an integrated healthcare delivery system.
A perspective on the current FDA guidance for diabetes therapies.
Increased care fragmentation among chronically ill, commercially insured patients is associated with higher costs and lower quality of care.
Program that enhances personalized and patient-centered preventive care at a busy inner-city primary care clinic may be associated with improved health outcomes.
Precision medicine is increasingly being utilized in oncology. Aurora Health Care has implemented Syapse software to integrate molecular data into the electronic health record to accommodate precision medicine findings.
Disease management programs for diabetes can improve some processes of care, but they do not improve intermediate outcomes beyond doubt.
There is widespread interest in understanding the role of health care in meeting social needs. This study examines community-wide activities, resources, and information technology used to manage social care.
This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.
Implementation of payment reform, without a corresponding change to coverage, benefit, and other payment requirements, creates conflicting incentives that may nullify the intended aim of payment reform: to improve health outcomes, while saving costs.
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.